Feb. 21, 2019—In addition to establishing potency, the team’s tests on cells and, later, mice showed that even high doses of the compound caused no ill effects.
Feb. 9, 2017—Vanderbilt University Medical Center (VUMC) is the first in the state to enroll patients in a clinical trial testing the effectiveness of the newest implantable device used to reduce stroke risk in patients with non-valvular atrial fibrillation (AF), the most common form of arrhythmia.
Jan. 14, 2016—Björn Knollmann, M.D., Ph.D., has been named director of the newly formed Vanderbilt Center for Arrhythmia Research and Therapeutics (VanCART).
May. 12, 2014—A particular anti-arrhythmia drug provides a targeted treatment for certain forms of atrial fibrillation.
Apr. 11, 2013—The state of Michael Stanbery’s health was shocking.
Feb. 7, 2013—A team led by Vanderbilt University investigators has discovered two new genes — both coding for the signaling protein calmodulin — associated with severe early-onset disorders of heart rhythm.
May. 21, 2012—Vanderbilt researchers have discovered a rare, but important risk posed by the antibiotic azithromycin, commonly called a “Z-pack.” The study found a 2.5-fold higher risk of death from cardiac arrhythmia in the first five days of taking azithromycin when compared with another common antibiotic or no antibiotics at all.